CA3255777A1 - METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE - Google Patents

METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE

Info

Publication number
CA3255777A1
CA3255777A1 CA3255777A CA3255777A CA3255777A1 CA 3255777 A1 CA3255777 A1 CA 3255777A1 CA 3255777 A CA3255777 A CA 3255777A CA 3255777 A CA3255777 A CA 3255777A CA 3255777 A1 CA3255777 A1 CA 3255777A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
membered heteroaryl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3255777A
Other languages
English (en)
French (fr)
Inventor
Michela Gallagher
Shi-Jiang Li
Arnold Bakker
Sharon Rosenzweig-Lipson
Original Assignee
Medical College of Wisconsin
Johns Hopkins University
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin, Johns Hopkins University, Agenebio Inc filed Critical Medical College of Wisconsin
Publication of CA3255777A1 publication Critical patent/CA3255777A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3255777A 2022-04-01 2023-04-03 METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE Pending CA3255777A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326773P 2022-04-01 2022-04-01
US63/326,773 2022-04-01
PCT/US2023/017348 WO2023192686A1 (en) 2022-04-01 2023-04-03 Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performance

Publications (1)

Publication Number Publication Date
CA3255777A1 true CA3255777A1 (en) 2023-10-05

Family

ID=88203560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3255777A Pending CA3255777A1 (en) 2022-04-01 2023-04-03 METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE

Country Status (9)

Country Link
US (1) US20250228820A1 (https=)
EP (1) EP4504176A1 (https=)
JP (1) JP2025511277A (https=)
CN (1) CN119730849A (https=)
AU (1) AU2023243233A1 (https=)
CA (1) CA3255777A1 (https=)
IL (1) IL316051A (https=)
MX (1) MX2024012122A (https=)
WO (1) WO2023192686A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584115A (zh) * 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法
WO2025148578A1 (zh) * 2024-01-09 2025-07-17 浙江同源康医药股份有限公司 布立西坦口腔溶膜速释制剂组合物及其制剂和用途
CN118518805B (zh) * 2024-07-25 2024-09-24 成都诺和晟泰生物科技有限公司 一种左乙拉西坦口服溶液中右乙拉西坦的检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) * 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MA50634A (fr) * 2015-05-22 2021-04-28 Agenebio Inc Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam
CN116075302A (zh) * 2020-07-10 2023-05-05 艾吉因生物股份有限公司 GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法

Also Published As

Publication number Publication date
JP2025511277A (ja) 2025-04-15
WO2023192686A1 (en) 2023-10-05
MX2024012122A (es) 2025-01-09
AU2023243233A1 (en) 2024-11-14
EP4504176A1 (en) 2025-02-12
IL316051A (en) 2024-11-01
CN119730849A (zh) 2025-03-28
US20250228820A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
CA3255777A1 (en) METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE
JP7108146B2 (ja) 新規メチルキナゾリノン誘導体
KR101960624B1 (ko) Hiv의 치료를 위한 이소퀴놀린 화합물
JP2025511277A5 (https=)
JP2021191798A (ja) Ｈｉｖカプシド阻害剤の固体形態
JP2024153683A (ja) ＮａＶ１．８を阻害するピリジンカルボキサミド化合物
JP2024138443A (ja) Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
TWI656122B (zh) 作為ｈｉｖ整合酶抑制劑之稠合三環雜環化合物
JP2021531256A (ja) ＮａＶ１．８を阻害するピリダジン化合物
JP2019112436A (ja) ルキソリチニブの徐放性投薬形態
US20240285596A1 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
JP2019511502A (ja) デングウイルス複製阻害剤としての置換インドール化合物誘導体
AU2016232705A1 (en) Compounds and methods for the enhanced degradation of targeted proteins
BR112019020175A2 (pt) Derivados de indolina substituídos como inibidores da replicação viral da dengue
CA2532347C (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
ZA200308783B (en) Quinoline derivatives as ligands for the neuropeptide Y receptor.
KR20190117790A (ko) 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
CN104447867B (zh) 一种噻吩并哌啶衍生物、制备方法及其应用
WO2018233620A1 (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
CA2489847A1 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
JP7737991B2 (ja) Ｅｇｆｒ阻害剤
CN115484956A (zh) 使用ulk1/2抑制剂的单一疗法和联合疗法
AU2015295313A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JP2021530525A (ja) ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
ZA200404628B (en) HIV integrase inhibitors.

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241001

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250215

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250215

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328